4.2 Article

Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials

期刊

PHARMACEUTICAL STATISTICS
卷 21, 期 3, 页码 671-690

出版社

WILEY
DOI: 10.1002/pst.2194

关键词

adaptive trials; clinical trial simulation; combination therapy; platform trials

资金

  1. Innovative Medicines Initiative (IMI) 2 Joint Undertaking (JU) [853966]
  2. European Union
  3. EFPIA
  4. Children's Tumor Foundation
  5. Global Alliance for TB Drug Development non-profit organization, Springworks Therapeutics Inc.
  6. Novartis

向作者/读者索取更多资源

Platform trials are gaining popularity for drug development, but many statistical questions related to their design remain unanswered. The definition of error rates is not straightforward and different design parameters and assumptions strongly influence the operating characteristics of platform trials.
Platform trials have become increasingly popular for drug development programs, attracting interest from statisticians, clinicians and regulatory agencies. Many statistical questions related to designing platform trials-such as the impact of decision rules, sharing of information across cohorts, and allocation ratios on operating characteristics and error rates-remain unanswered. In many platform trials, the definition of error rates is not straightforward as classical error rate concepts are not applicable. For an open-entry, exploratory platform trial design comparing combination therapies to the respective monotherapies and standard-of-care, we define a set of error rates and operating characteristics and then use these to compare a set of design parameters under a range of simulation assumptions. When setting up the simulations, we aimed for realistic trial trajectories, such that for example, a priori we do not know the exact number of treatments that will be included over time in a specific simulation run as this follows a stochastic mechanism. Our results indicate that the method of data sharing, exact specification of decision rules and a priori assumptions regarding the treatment efficacy all strongly contribute to the operating characteristics of the platform trial. Furthermore, different operating characteristics might be of importance to different stakeholders. Together with the potential flexibility and complexity of a platform trial, which also impact the achieved operating characteristics via, for example, the degree of efficiency of data sharing this implies that utmost care needs to be given to evaluation of different assumptions and design parameters at the design stage.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据